References
- Kerr D. Generic drugs: their role in better value cancer care. Ann Oncol 2013;24(Suppl. 5):v5.
- Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 2013;121:4439–4442.
- Lopes Gde L. Cost comparison and economic implications of commonly used originator and generic chemotherapy drugs in India. Ann Oncol 2013;24(Suppl. 5):v13–v16.
- Chatterjee P. India's patent case victory rattles Big Pharma. Lancet 2013;381:1263.
- Kapczynski A. Engineered in India–patent law 2.0. N Engl J Med 2013;369:497–499.
- Relman AS, Angell M. America's other drug problem. New Republ 2002;Dec 16:27–41. Available from: www.newrepublic.com/article/americas-other-drug-problem
- Saavedra D, Vizcarra F. Deleterious effects of non-branded versions of imatinib used for the treatment of patients with chronic myeloid leukemia in chronic phase: a case series on an escalating issue impacting patient safety. Leuk Lymphoma 2014;55;2813–2816.
- Alwan AF, Matti BF, Naji AS, et al. Prospective single-center study of chronic myeloid leukemia in chronic phase: switching from branded imatinib to a copy drug and back. Leuk Lymphoma 2014;55:2830–2834.
- Generic imatinib. BC Cancer Agency provincial systemic therapy update. 2013;16:1–2. Available from: www.bccancer.bc.ca/NR/rdonlyres/6689653F-6689620F6689655-6684882-A6689659AA-6689656F6689690F6689657EA6689394/6666704/STUpdateOctober6682013_FINAL.pdf
- Mailankody S, Prasad V. Comparative effectiveness questions in oncology. N Engl J Med 2014;370:1478–1481.
- Kay M. Indian generics manufacturer Ranbaxy agrees to pay $500m to settle US fraud and drug safety charges. BMJ 2013;346:f3536.
- Eskazan AE, Elverdi T, Yalniz FF, et al. The efficacy of generic formulations of imatinib mesylate in the treatment of chronic myeloid leukemia. Leuk Lymphoma 2014;55:2935–2937.
- Malhotra H, Sharma P, Bhargava S, et al. Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia. Leuk Lymphoma 2014;55:2614–2619.